Tele2’s updated fair value range has shifted from SEK 164.33 to SEK 169.91, putting more focus on how much room investors see above current price targets. This sits against mixed analyst actions, with...

The latest tweak to fair value and what it signals The fair value estimate for Xvivo Perfusion has been trimmed slightly from SEK 319.6 to SEK 317.6, with a modestly higher discount rate and a small r...

Swedish Orphan Biovitrum's updated narrative now centers on a slightly higher fair value estimate of SEK 367.09, up from SEK 360.36, paired with a marginally higher discount rate of 5.34% that reflect...

Xvivo Perfusion’s latest rating upgrade comes with a refreshed narrative rather than a fundamental shift in its intrinsic value, with the fair value estimate holding steady at SEK 319.6 while the form...

Xvivo Perfusion’s stock price target has recently been reaffirmed at SEK 319.6 following the latest analyst review, with a slight increase in the discount rate to 5.77 percent. Revenue growth projecti...

Xvivo Perfusion’s Fair Value Estimate has recently been revised downward from SEK 345.6 to SEK 322.6. This reflects a modest adjustment in analysts’ price targets. The revision also comes with a sligh...